These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20857352)

  • 1. Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment.
    Coleman S; Peethambaram PP; Jatoi A
    J Cancer Educ; 2011 Sep; 26(3):474-7. PubMed ID: 20857352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
    He JX; Yang CH; Miao ZH
    Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP and PARG inhibitors--new therapeutic targets in cancer treatment.
    Fauzee NJ; Pan J; Wang YL
    Pathol Oncol Res; 2010 Dec; 16(4):469-78. PubMed ID: 20383759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of PARP inhibitors in oncology.
    Rodon J; Iniesta MD; Papadopoulos K
    Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK; Yap TA; de Bono JS
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
    Sandhu SK; Yap TA; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
    Peralta-Leal A; Rodríguez MI; Oliver FJ
    Clin Transl Oncol; 2008 Jun; 10(6):318-23. PubMed ID: 18558578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for cancer using PARP inhibitors.
    Lord CJ; Ashworth A
    Curr Opin Pharmacol; 2008 Aug; 8(4):363-9. PubMed ID: 18644251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
    Anders CK; Winer EP; Ford JM; Dent R; Silver DP; Sledge GW; Carey LA
    Clin Cancer Res; 2010 Oct; 16(19):4702-10. PubMed ID: 20858840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase inhibition: past, present and future.
    Curtin NJ; Szabo C
    Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
    Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors blaze a trail in difficult-to-treat cancers.
    Kling J
    Nat Biotechnol; 2009 Sep; 27(9):784-6. PubMed ID: 19741614
    [No Abstract]   [Full Text] [Related]  

  • 17. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
    Wang B; Qian H; Yiu SM; Sun J; Zhu G
    Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.